论文部分内容阅读
目的观察祛瘀生新方联合美沙拉秦治疗轻中度溃疡性结肠炎(UC)的临床疗效。方法将72例轻中度溃疡性结肠炎患者随机分为治疗组与对照组,每组36例。治疗组予祛瘀生新方联合美沙拉秦治疗,对照组仅予美沙拉秦治疗。两组疗程均为1个月,观察临床疗效,比较改良Mayo评分、UC生活质量评分及相关生化指标C反应蛋白(CRP)、红细胞沉降率(ESR)的变化情况。结果①试验期间,治疗组脱落1例(因失访),最终完成试验者对照组36例、治疗组35例。②治疗组、对照组临床总有效率分别为88.57%、75.00%;组间临床疗效比较,治疗组明显优于对照组(P<0.05)。③治疗前后组内比较,两组改良Mayo评分差异均有统计学意义,均明显下降(P<0.05)。组间治疗前后差值比较,治疗组评分改变明显多于对照组(P<0.05)。④组间治疗后比较,UC生活质量评分(肠道症状、全身症状)差异有统计学意义,治疗组明显高于对照组(P<0.05)。⑤组间治疗后比较,CRP、ESR水平差异有统计学意义,治疗组明显低于对照组(P<0.05)。结论祛瘀生新方联合美沙拉秦治疗轻中度溃疡性结肠炎,可明显改善活动期临床症状,抑制体内炎症反应,提高患者生活质量。
Objective To observe the clinical curative effect of Quyu Shengxifang combined with Mesalazine in the treatment of mild to moderate ulcerative colitis (UC). Methods 72 patients with mild to moderate ulcerative colitis were randomly divided into treatment group and control group, 36 cases in each group. The treatment group was treated with melasmahide by Qushi Xin Fang and the control group only with mesalazine. The course of treatment was 1 month. The clinical curative effect was observed. The changes of modified Mayo score, UC quality of life score and related biochemical indexes of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were compared. Results ① During the experiment, one patient in the treatment group was lost (due to lost follow-up), 36 patients in the control group and 35 patients in the treatment group were finally completed. ② The total clinical effective rates of the treatment group and the control group were 88.57% and 75.00% respectively. The clinical efficacy of the treatment group was significantly better than that of the control group (P <0.05). ③ Before and after treatment, the modified Mayo scores of the two groups were significantly different (all P <0.05). Before and after treatment difference between groups, the treatment group scores significantly more than the control group (P <0.05). ④ After treatment, the scores of UC quality of life (intestinal symptoms, systemic symptoms) were significantly different between the two groups, and the treatment group was significantly higher than that of the control group (P <0.05). ⑤Comparison between groups after treatment, CRP, ESR levels were significantly different, the treatment group was significantly lower than the control group (P <0.05). Conclusion Qushi new prescription combined with mesalamine treatment of mild to moderate ulcerative colitis can significantly improve clinical symptoms, inhibit the body’s inflammatory response and improve the quality of life of patients.